These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 22175694

  • 1. Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A.
    Liu W, Zhou J, Geng G, Shi Q, Sauriol F, Wu JH.
    J Med Chem; 2012 Jan 26; 55(2):971-5. PubMed ID: 22175694
    [Abstract] [Full Text] [Related]

  • 2. Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells.
    Won SH, Lee HJ, Jeong SJ, Lü J, Kim SH.
    Phytother Res; 2012 May 26; 26(5):669-74. PubMed ID: 21997969
    [Abstract] [Full Text] [Related]

  • 3. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
    Abdelbaqi K, Lack N, Guns ET, Kotha L, Safe S, Sanderson JT.
    Prostate; 2011 Sep 15; 71(13):1401-12. PubMed ID: 21321979
    [Abstract] [Full Text] [Related]

  • 4. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T, Bertolini R, Nichols SE, Setoud R, Frey FJ, Baker ME, Frey BM.
    Biochem Pharmacol; 2011 Dec 01; 82(11):1651-62. PubMed ID: 21907706
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A.
    J Mol Endocrinol; 2009 May 01; 42(5):429-35. PubMed ID: 19223455
    [Abstract] [Full Text] [Related]

  • 6. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 7. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.
    Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040
    [Abstract] [Full Text] [Related]

  • 8. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 01; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 9. 4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor.
    Wakabayashi K, Imai K, Miyachi H, Hashimoto Y, Tanatani A.
    Bioorg Med Chem; 2008 Jul 15; 16(14):6799-812. PubMed ID: 18571420
    [Abstract] [Full Text] [Related]

  • 10. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer.
    Jiang C, Lee HJ, Li GX, Guo J, Malewicz B, Zhao Y, Lee EO, Lee HJ, Lee JH, Kim MS, Kim SH, Lu J.
    Cancer Res; 2006 Jan 01; 66(1):453-63. PubMed ID: 16397261
    [Abstract] [Full Text] [Related]

  • 11. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.
    Prostate; 2004 Feb 01; 58(2):130-44. PubMed ID: 14716738
    [Abstract] [Full Text] [Related]

  • 12. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D, Farquhar R, Guo Z, Qiu Y, Brodie AM.
    J Med Chem; 2005 Apr 21; 48(8):2972-84. PubMed ID: 15828836
    [Abstract] [Full Text] [Related]

  • 13. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT, Budunova I.
    Cancer Res; 2008 Jun 15; 68(12):4763-73. PubMed ID: 18559523
    [Abstract] [Full Text] [Related]

  • 14. Antiproliferative, antiandrogenic and cytotoxic effects of novel caffeic acid derivatives in LNCaP human androgen-dependent prostate cancer cells.
    Sanderson JT, Clabault H, Patton C, Lassalle-Claux G, Jean-François J, Paré AF, Hébert MJ, Surette ME, Touaibia M.
    Bioorg Med Chem; 2013 Nov 15; 21(22):7182-93. PubMed ID: 24080105
    [Abstract] [Full Text] [Related]

  • 15. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L, Giocanti N, Hennequin C, Favaudon V.
    Prostate; 2010 Mar 01; 70(4):401-11. PubMed ID: 19902473
    [Abstract] [Full Text] [Related]

  • 16. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.
    Prostate; 2008 May 15; 68(7):793-801. PubMed ID: 18324645
    [Abstract] [Full Text] [Related]

  • 17. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N.
    Prostate; 2008 Feb 15; 68(3):287-95. PubMed ID: 18163430
    [Abstract] [Full Text] [Related]

  • 18. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M.
    Cancer Res; 2003 Jan 01; 63(1):149-53. PubMed ID: 12517791
    [Abstract] [Full Text] [Related]

  • 19. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
    Attardi BJ, Burgenson J, Hild SA, Reel JR.
    Mol Cell Endocrinol; 2004 Jul 30; 222(1-2):121-32. PubMed ID: 15249132
    [Abstract] [Full Text] [Related]

  • 20. [Up-regulates the expression of maspin gene in prostate cancer cell line LNCaP].
    Shi P, Chen WW, Hu XY, Yu CX, Zhang PJ, Jiang AL, Zhang JY.
    Yao Xue Xue Bao; 2006 Dec 30; 41(12):1152-6. PubMed ID: 17290611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.